Home

Welcome to Quest PharmaTech Inc.

Quest PharmaTech is a publicly traded (QPT:TSXV), Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies. Quest is developing an antibody licensed from the University of Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications.

Notes:

1. OncoQuest transferred its immunotherapy assets to OncoQuest Pharmaceuticals, Inc. (“OQP”) in return for convertible bonds and a corporate bond of OQP with a face value of Cdn$385 million. The OQP bonds will be exchanged into bonds of Canaria Bio M and are planned to be exchangeable ultimately into shares of Canaria Bio. OncoQuest issued an in-kind dividend of OQP bonds (face value Cdn$320 million) to its shareholders on January 14, 2022. Quest’s portion, fully diluted, is approximately KRW 129.1 billion face value of OQP bonds ($cdn 136M).

2. OncoVent has an estimated book value of Cdn$11.8 million. Quest has an 10.67 % direct ownership interest in OncoVent. Quest also has a 12% indirect interest through its ownership interest in OncoQuest. OncoQuest owns 29% of OncoVent.

Press releases 2022

September 28, 2022
Quest PharmaTech Announces Sale of Bioceltran Investment and Return of Photodynamic Therapy Technology License

April 19, 2022
Quest PharmaTech Provides Corporate Update

Press releases 2021

September 1, 2021
OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer

July 7, 2021
Quest PharmaTech Announces Results from AGM

June 1, 2021
Quest PharmaTech Announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists

March 26, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

February 2, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

January 5, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

Press releases 2020

November 9, 2020
Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company’s Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer

June 4, 2020
Quest Provides Corporate Update

May 29, 2020
Quest Provides Additional Information on OncoQuest Transaction and Announces Delay in Annual Filings

April 22, 2020
OncoQuest Signs a Definitive Agreement to Sell Drug Portfolio to Dual Industrial for U.S. $300 Million and Commitment to Fund the Oregovomab Phase 3 Clinical Trial in Frontline Ovarian Cancer

March 24, 2020
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company’s Lead Investigational Drug in Frontline Ovarian Cancer

March 13, 2020
OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.